Seres Therapeutics (NASDAQ:MCRB - Get Free Report) will be issuing its quarterly earnings data before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.
Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last announced its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.08. During the same quarter last year, the business earned $0.36 EPS. On average, analysts expect Seres Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Seres Therapeutics Stock Down 5.3 %
NASDAQ:MCRB traded down $0.04 during trading hours on Thursday, hitting $0.72. 2,166,173 shares of the stock were exchanged, compared to its average volume of 4,360,309. The company has a market capitalization of $121.73 million, a P/E ratio of -0.63 and a beta of 2.06. Seres Therapeutics has a twelve month low of $0.54 and a twelve month high of $2.05. The company's 50 day moving average is $0.88 and its two-hundred day moving average is $0.92.
Wall Street Analysts Forecast Growth
MCRB has been the topic of a number of analyst reports. Chardan Capital reiterated a "buy" rating and issued a $1.25 price target on shares of Seres Therapeutics in a research report on Wednesday, August 14th. StockNews.com cut shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. lowered Seres Therapeutics from a "neutral" rating to an "underweight" rating in a report on Thursday, October 24th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Seres Therapeutics in a research report on Friday, September 13th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $5.08.
Read Our Latest Report on Seres Therapeutics
About Seres Therapeutics
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
Recommended Stories
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
